Addition of the antidepressant drug Viloxazine (VLX) to six epileptic patients stabilized on oxcarbazepine (OXCZ) therapy was evaluated with respect to serum levels of OXCZ and its two major metabolites MHD and DHD. The study was carried out in a randomized, double-blind, placebo-controlled design. Administration of VLX resulted in an increase in MHD levels by 11% on average and a concomitant decrease in plasma DHD by 31% on average. Steady-state levels of OXCZ remained stable throughout the study. These changes in plasma OXCZ metabolites were not associated with clinical manifestations.
|Translated title of the contribution||The effect of viloxazine on the serum levels of Oxcarbazepine and its metabolites|
|Number of pages||2|
|Journal||Bollettino - Lega Italiana contro l'Epilessia|
|Publication status||Published - 1993|
ASJC Scopus subject areas
- Clinical Neurology